The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2021 | Patient selection in the treatment of NHL
Ulrich Jäger, MD, Medical University of Vienna, Vienna, Austria, explains the rationale behind patient selection and treatment of non-Hodgkin lymphoma in the era of chimeric antigen receptor (CAR) T-cell therapy, highlighting risk factors for non-response such as extranodal involvement and a high number of prior lines of therapy, as well as commenting on a risk stratification model. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
Transcript
For NHL, I think, of course you have to look at the type of NHL for the diffuse large B-cell lymphomas, as I said, we have some indications what the major risk factors for a non-response are. And that, for instance, is [inaudible] disease, that’s later lines of treatment, that’s extra nodal involvement of the lymphoma. We’ve also shown that for instance, high expression of Myc in the tumor is a poor prognostic sign...
For NHL, I think, of course you have to look at the type of NHL for the diffuse large B-cell lymphomas, as I said, we have some indications what the major risk factors for a non-response are. And that, for instance, is [inaudible] disease, that’s later lines of treatment, that’s extra nodal involvement of the lymphoma. We’ve also shown that for instance, high expression of Myc in the tumor is a poor prognostic sign. And all these factors will help us to select patients. Some of the factors can even be combined like in the French [inaudible] index, [inaudible] disease plus extra nodal sites. And we have tried to combine LDH and histology and namely Myc expression into an index where for instance, patients with a low Myc expression and a normal LDH have a chance of 75% of staying in a long-term response. And so, moving forward. As I previously said, it’s the fine balance between selecting the right patient and not, let’s say, being over-restrictive to exclude patients who would actually profit.
Read more...
